J&J Q2 2013 Sales Nearly Reach $18 Billion

Johnson & Johnson (J&J) announced sales of $17.9 billion for the second quarter of 2013, an increase of 8.5% as compared to the second quarter of 2012. Operational results increased 10% and the negative impact of currency was 1.5%. Domestic sales increased 8%, while international sales increased 9%, reflecting operational growth of 11.8% and a negative currency impact of 2.8%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide operational sales growth was 5.6%.

“Our strong second-quarter results reflect the progress we’ve made against our near-term priorities of delivering on our financial commitments, restoring a reliable supply of over-the-counter products to consumers, continuing the successful integration of Synthes and building on the momentum in our pharmaceutical business,” said Alex Gorsky, J&J's chairman and CEO. “Our talented colleagues at Johnson & Johnson continue to bring meaningful innovations to patients and consumers around the world and have positioned us well to deliver sustainable growth.”

The company increased its earnings guidance for full-year 2013 to $5.40–5.47 per share, and such guidance excludes the impact of special items.

For its worldwide consumer division—which includes brands Neutrogena, Clean & Clear, Lubriderm, RoC, skinID and Aveeno, as well as baby care brand Johnson's—J&J recorded sales of $3.7 billion for the second quarter, which represented an increase of 1.1% versus the prior year consisting of an operational increase of 1.7% and a negative impact from currency of 0.6%. Domestic sales increased 1%, and international sales increased 1.1%, which reflected an operational increase of 2% and a negative currency impact of 0.9%.

Positive contributors to operational results of the worldwide consumer division included upper respiratory over-the-counter medicines; Tylenol and Motrin analgesics; international sales of Listerine mouthwash; baby care products and women’s sanitary protection products.

Click here to find more details of this second quarter 2013 financial report from Johnson & Johnson.

More in News